Related Experiment Video

Updated: May 8, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

A Case of GLP-1 Receptor Agonist-Induced Lithium Neurotoxicity

Anuhya Kotta1, Sahar Ashraf2, Mehreen Khan1,3

  • 1Department of Psychiatry, UT Southwestern Medical Center, Dallas, TX.

Journal of Psychiatric Practice
|May 7, 2026
PubMed

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may help bipolar disorder patients. However, this case highlights a risk of GLP-1 RA-induced lithium neurotoxicity, necessitating careful monitoring.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Endocrinology

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are investigated for metabolic syndrome and cardiovascular risks in bipolar disorder patients.
  • GLP-1 RAs are FDA-approved for type 2 diabetes, cardiovascular disease, obesity, and chronic kidney disease.
  • Expanding research suggests potential use in bipolar disorder, particularly for patients on lithium carbonate.

Purpose of the Study:

  • To report a case of GLP-1 RA-induced lithium neurotoxicity.
  • To emphasize the need for vigilance regarding lithium toxicity in patients co-administered lithium and GLP-1 RAs.

Main Methods:

  • Case report detailing a patient experiencing lithium neurotoxicity.
  • Review of literature on GLP-1 RAs and lithium interactions.

Main Results:

  • A case of neurotoxicity was identified in a patient receiving both lithium and a GLP-1 RA.
  • This suggests a potential drug interaction that can lead to elevated lithium levels.

Conclusions:

  • The coadministration of lithium and GLP-1 RAs may increase the risk of lithium neurotoxicity.
  • Enhanced monitoring for lithium toxicity is crucial in patients receiving both medications.
  • Further research is warranted to understand this interaction and guide clinical practice.
Keywords:
GLP-1 receptor agonistslithiummoodtoxicityweight loss

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...